[AFMD] Affimed N.V.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.85 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart AFMD

Refresh chart

Strongest Trends Summary For AFMD

AFMD is in the long-term down -72% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company?s product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The

Fundamental Ratios
Shares Outstanding EPS-0.9 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-2.22
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-222.01% ROE13.62% ROI
Current Ratio0.26 Quick Ratio0.26 Long Term Debt/Equity Debt Ratio-0.19
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-40 K Cash From Operating Activities-3.92 M Gross Profit
Net Profit-1.48 M Operating Profit-2 M Total Assets39.29 M Total Current Assets38.29 M
Total Current Liabilities4.13 M Total Debt4.51 M Total Liabilities8.64 M Total Revenue2.54 M
Technical Data
High 52 week6.15 Low 52 week1.45 Last close3.37 Last change-3.44%
RSI50.52 Average true range0.17 Beta1.44 Volume378.6 K
Simple moving average 20 days-1.65% Simple moving average 50 days-10.51% Simple moving average 200 days-6.23%
Performance Data
Performance Week-4.8% Performance Month-2.32% Performance Quart-1.46% Performance Half-10.61%
Performance Year38.97% Performance Year-to-date8.36% Volatility daily2.3% Volatility weekly5.13%
Volatility monthly10.52% Volatility yearly36.44% Relative Volume414.03% Average Volume915.81 K
New High New Low


2019-06-15 12:38:28 | The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

2019-06-12 05:30:00 | Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland

2019-06-04 16:01:00 | Affimed Announces Annual General Meeting of Shareholders

2019-06-03 05:00:00 | Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagen’s Patented Mammalian Expression Technology

2019-05-29 05:00:00 | Affimed to Present at the Jefferies 2019 Healthcare Conference

2019-05-23 14:25:06 | Affimed AFMD Earnings and Sales Exceed Estimates in Q1

2019-05-22 15:44:58 | Edited Transcript of AFMD earnings conference call or presentation 22-May-19 12:30pm GMT

2019-05-22 15:23:14 | Affimed N.V. AFMD Q1 2019 Earnings Call Transcript

2019-05-22 08:45:12 | Affirmed Therapeutics AFMD Beats Q1 Earnings and Revenue Estimates

2019-05-22 07:58:00 | Affimed to end cancer program and focus on innate immunity portfolio, shares slide about 10%

2019-05-22 07:30:00 | Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio; Reports First Quarter 2019 Financial Results and Operational Progress

2019-05-21 14:16:18 | Affimed Q1 Earnings Preview

2019-05-16 05:00:00 | Affimed Announces First Quarter 2019 Financial Results and Corporate Update Conference Call on May 22, 2019

2019-05-14 10:30:02 | Affirmed Therapeutics AFMD May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-05-13 09:17:01 | What's in Store for Affimed AFMD This Earnings Season?

2019-04-30 09:00:01 | Affirmed Therapeutics AFMD Moves to Buy: Rationale Behind the Upgrade

2019-04-27 09:16:37 | If You Had Bought Affimed NASDAQ:AFMD Shares A Year Ago You'd Have Made 62%

2019-04-17 16:05:00 | Affimed Provides Regulatory Update on AFM11 Clinical Program

2019-04-09 08:48:12 | Implied Volatility Surging for Affimed AFMD Stock Options

2019-04-01 08:00:00 | Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research AACR 2019 Annual Meeting

2019-03-27 14:26:08 | Edited Transcript of AFMD earnings conference call or presentation 27-Mar-19 12:30pm GMT

2019-03-27 13:49:31 | Affimed N.V. AFMD Q4 2018 Earnings Conference Call Transcript

2019-03-27 07:30:00 | Affimed Reports 2018 Financial Results and Operational Progress

2019-03-20 05:00:00 | Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019

2019-03-19 07:40:42 | The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

2019-03-19 05:00:00 | Affimed Announces Milestone Payment from Genentech and ROCK® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity

2019-03-12 10:30:02 | Will Affirmed Therapeutics AFMD Report Negative Q4 Earnings? What You Should Know

2019-02-27 17:01:52 | Affimed to Present Data on AFM13 and AFM24 at AACR Annual Meeting 2019

2019-02-21 07:30:00 | Affimed to Present at Upcoming Investor Conferences

2019-02-19 14:34:00 | Trading Notes for Select Stocks

2019-01-04 08:30:00 | Affimed to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-24 08:50:01 | Do Options Traders Know Something About Affimed AFMD Stock We Don't?

2018-12-23 07:53:42 | Affimed NV AFMD: Are Hedge Funds Right About This Stock?

2018-12-07 11:30:00 | Affimed Announces U.S. Registrational Pathway and Updated Clinical Development Plan for AFM13 at R&D Day

2018-12-03 11:30:00 | Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

2018-11-28 05:00:00 | Affimed to Host Research & Development Day on Friday, December 7, 2018 in New York City

2018-11-26 10:36:00 | My Stock of the Week: Affirmed N.V.

2018-11-23 14:06:57 | Our Take On Affimed NV’s NASDAQ:AFMD CEO Salary

2018-11-15 08:10:00 | Report: Exploring Fundamental Drivers Behind Affimed N.V, Sensus Healthcare, Lifetime Brands, SigmaTron International, Salem Media Group, and Origin Agritech — New Horizons, Emerging Trends, and Upcoming Developments

2018-11-09 09:18:02 | Implied Volatility Surging for Affimed AFMD Stock Options

2018-11-08 07:31:42 | Edited Transcript of AFMD earnings conference call or presentation 7-Nov-18 1:30pm GMT

2018-11-08 05:35:44 | Affimed to Present at the Jefferies 2018 London Healthcare Conference

2018-11-07 11:05:04 | Affirmed Therapeutics AFMD Reports Q3 Loss, Tops Revenue Estimates

2018-11-07 07:31:03 | Affimed Reports Financial Results for Third Quarter 2018 and Operational Progress

2018-11-01 09:16:59 | Affimed Announces Oral Presentation and Five Poster Presentations at the 2018 American Society of Hematology Annual Meeting

2018-10-31 06:01:41 | Affimed Announces Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018

2018-10-10 10:07:02 | Company News For Oct 10, 2018

2018-10-09 10:01:02 | Affimed Down After Clinical Hold on Two Early-Stage Studies

2018-10-09 09:16:55 | [$$] Stocks to Watch: Alphabet, Exxon, Papa John's, Tesla

2018-10-09 08:43:12 | Implied Volatility Surging for Affimed AFMD Stock Options